Boston reports zero restenosis for drug-eluting stent
This article was originally published in Clinica
Executive Summary
Boston Scientific last week staked its claim in the race for a piece of the drug coated stent market, announcing it had so far completely avoided the reclogging of coronary arteries with its paclitaxel-eluting coronary stent.